Company: MDCXW
Filing Date: 2025-05-13
Form Type: 424B3
Source: 0001062993-25-009166
Chunk: 23

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-13
Form: 424B3
Chunk 23
---
,940,994 | ) |     |                          (1,176,933 | ) |     | (2,764,061 | ) |
| Cash provided by financing activities |     |  3,759,101 |   |     |                                   - |   |     |  3,759,101 |   |
| Net change in cash during the period  |     |   (181,893 | ) |     |                          (1,176,933 | ) |     |    995,040 |   |
| Cash, beginning of the period         |     |  4,164,323 |   |     |                           1,719,338 |   |     |  2,444,985 |   |
| Cash, end of the period               |     |  3,982,430 |   |     |                             542,405 |   |     |  3,440,025 |   |

Cash flows used in operating activities Cash flows used in operating activities for the three months ended March 31, 2025 were $3,940,994 compared to cash flows used in operating activities of $1,176,933 for the three months ended March 31, 2024. The increase is primarily due to increased spending on research and development activities for our SKNJCT-003 study and trials and increased general and administrative expenses related to our recent initial public offering and resulting U.S. reporting obligations. Cash flows provided by financing activities Cash flows provide by financing activities for the three months ended March 31, 2025, were $3,759,101 due to proceeds from issuance of common shares and warrants, net of offering costs from the Regulation A Offering. The Company did not have any financing activities for the three months ended March 31, 2024. Contractual Obligations We have no significant contractual arrangements other than those noted in our financial statements. Off-Balance Sheet Arrangements As of March 31, 2025, we have not entered into any off-balance sheet arrangements. Critical Accounting Policies Critical Accounting Policies and Estimates We periodically review our financial reporting and disclosure practices and accounting policies to ensure that they provide accurate and transparent information relative to the current economic and business environment. As part of this process, we have reviewed our selection, application and communication of critical accounting policies and financial disclosures. Management has discussed the development and selection of the critical accounting policies with our audit committee, and our audit committee has reviewed the disclosure relating to